Is the prescribing behavior of Chinese physicians driven by financial incentives?

Social Science and Medicine

Volumn 120, Issue , 2014, Pages 40-48

  Chen, Chun ^a   Dong, Weizhen ^b,c   Shen, Jay J ^d   Cochran, Christopher ^d   Wang, Ying ^a   Hao, Mo ^a  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF WATERLOO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF NEVADA   (United States)

Author keywords

China; Drug price; Health policy; Pharmacoeconomics; Prescribing behavior

Indexed keywords

AMOXICILLIN; AMPICILLIN; CEFACLOR; CEFALEXIN; CEFAZOLIN; CEFEPIME; CEFIXIME; CEFMETAZOLE; CEFOPERAZONE; CEFOTIAM; CEFOXITIN; CEFPIRAMIDE; CEFRADINE; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLOXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN; PRESCRIPTION DRUG;

COST-BENEFIT ANALYSIS; DRUG PRESCRIBING; FINANCIAL SYSTEM; GOVERNMENT; HEALTH POLICY; HEALTH SERVICES; HEALTH WORKER; INCENTIVE; PRICE DYNAMICS;

ARTICLE; CHINESE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DATA ANALYSIS; DRUG COST; DRUG USE; FINANCIAL MANAGEMENT; GOVERNMENT REGULATION; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; MEDICAL FEE; PERSONNEL MANAGEMENT; PHYSICIAN ATTITUDE; PHYSICIAN INCOME; POLITICAL PARTICIPATION; PRESCRIPTION; REWARD; CHINA; CLINICAL PRACTICE; ECONOMICS; GENERAL PRACTITIONER; HOSPITAL; PHARMACOECONOMICS; REIMBURSEMENT; STATISTICS AND NUMERICAL DATA;

CHINA; YANGTZE BASIN;

CHINA; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; HEALTH POLICY; HOSPITALS, URBAN; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, PRIMARY CARE; PRESCRIPTION DRUGS; REIMBURSEMENT, INCENTIVE;

EID: 84907086665     PISSN: 02779536     EISSN: 18735347     Source Type: Journal    
DOI: 10.1016/j.socscimed.2014.05.033     Document Type: Article

References (50)

1. Beers M.H. The Merck Manual of Medical Information: 2nd Home Edition 2004, Simon & Schuster, New Jersey.
2. Brekke K.R., Grasdal A.L., Holma˚s T.H. Regulation and pricing of pharmaceuticals: reference pricing or price cap regulation?. Eur. Econ. Rev. 2009, 53:170-185.
3. Carney A., Portugheiz E., Shvartzman P. Nitrate prescriptions in primary care: are we over-prescribing? A pilot intervention. Harefuah 2012, 151:272.
4. Cars O., Mo¨lstad S., Melander A. Variation in antibiotic use in the European Union. Lancet 2001, 357:1851-1853.
5. Casey J.R., Pichichero M.E. Meta-analysis of cephalosporins versus penicillin for treatment of group A streptococcal tonsillopharyngitis in adults. Clin. Infect. Dis. 2004, 38:1526-1534.
6. Chen W., Tang S., Sun J., Ross-Degnan D., Wagner A.K. Availability and use of essential medicines in China: manufacturing, supply, and prescribing in Shandong and Gansu provinces. BMC Health Serv. Res. 2010, 10:211.
7. Cheng T.M. Explaining Shanghai's health care reforms, successes, and challenges. Health Aff. 2013, 32:2199-2204.
8. Currie J., Lin W., Zhang W. Patient knowledge and antibiotic abuse: evidence from an audit study in China. J. Health Econ. 2011, 30:933-949.
9. Dancer S. The problem with cephalosporins. J. Antimicrob. Chemother. 2001, 48:463-478.
10. Dong W. Tackling Healthcare Cost Issue with a Population Health Perspective: Challenges and Strategies 2012, August, Paper Presented at the Second ISA Forum of Sociology, ISA, Buenos Aires.
11. Downie L., Armiento R., Subhi R., Kelly J., Clifford V., Duke T. Community-acquired neonatal and infant sepsis in developing countries: efficacy of WHO's currently recommended antibiotics-systematic review and meta-analysis. Arch. Dis. Child. 2013, 98:146-154.
12. Ess S.M., Schneeweiss S., Szucs T.D. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003, 21:89-103.
13. Gong S. Evaluation and analysis of group procurement policy of drugs for hospitals in China. Chin. Health Policy Res. 2009, 4:14-21.
14. Guterman S., Davis K., Schoenbaum S., Shih A. Using medicare payment policy to transform the health system: a framework for improving performance. Health Aff. 2009, 28:w238-w250.
15. Kalo´ Z., Muszbek N., Bodrogi J., Bidlo´ J. Does therapeutic reference pricing always result in cost-containment?: the Hungarian evidence. Health Policy 2007, 80:402-412.
16. Langenbrunner J., Cashin C., O'Dougherty S. Designing and Implementing Health Care Provider Payment Systems: How-to Manuals 2009, World Bank Publications, Washington.
17. Li Y., An Y., Yang J., Liu F. Gram-positive cocci infection in surgical ICUs. Chin. J. Exp. Clin. Infect. Dis. (Electron. Ed.) 2009, 3:48-50.
18. Li Y., Xu J., Wang F., Wang B., Liu L., Hou W., Lu Z. Overprescribing in China, driven by financial incentives, results in very high use of antibiotics, injections, and corticosteroids. Health Aff. 2012, 31:1075-1082.
19. Lundin D. Moral hazard in physician prescription behavior. J. Health Econ. 2000, 19(5):639-662.
20. Meng Q., Cheng G., Silver L., Sun X., Rehnberg C., Tomson G. The impact of China's retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals. Health Policy Plan. 2005, 20:185-196.
21. Miller E.L. The penicillins: a review and update. J. Midwifery Womens Health 2002, 47:426-434.
22. Ministry of Health of the People's Republic of China Principles for Clinical Use of Antibiotics 2004, Ministry of Health, People's Republic of China, Beijing.
23. Ministry of Health of the People's Republic of China Yearbook of Chinese Health Statistics, 2012 2013, People's Health Press, Beijing.
24. Ministry of Health of the People's Republic of China Yearbook of Chinese Health Statistics, 2008 2009, People's Health Press, Beijing.
25. National Development and Reform Commission Notice of National Development and Reform Committee on the Reduction of Retail Prices of 24 Anti-infection Medicines 2004, National Development and Reform Commission, Beijing.
26. National Development and Reform Commission Chinese Regulations On Drug Prices Management 2010, Retrieved 29 June 2010, from:. http://health.sohu.com/20100629/n273160642.shtml.
27. Otoom S., Sequeira R. Health care providers' perceptions of the problems and causes of irrational use of drugs in two Middle East countries. Int. J. Clin. Pract. 2006, 60:565-570.
28. Palmer N., Pealing R., Ireland R., Martin M. Therapeutics: a study of therapeutic antibiotic prescribing in National Health Service general dental practice in England. Br. Dent. J. 2000, 188:554-558.
29. Qiao G., Lou J. Pharmacology 2010, Peking University Medical Press, Beijing.
30. Radyowijati A., Haak H. Improving antibiotic use in low-income countries: an overview of evidence on determinants. Soc. Sci. Med. 2003, 57:733-744.
31. Rietveld A.H., Haaijer-Ruskamp F.M. Policy options for cost containment of pharmaceuticals. Int. J. Risk Saf. Med. 2002, 15:29-54.
32. Schindler C., Krappweis J., Morgenstern I., Kirch W. Prescriptions of systemic antibiotics for children in Germany aged between 0 and 6 years. Pharmacoepidemiol. Drug. Saf. 2003, 12:113-120.
33. Schweitzer S.O. Pharmaceutical Economics and Policy 1997, Oxford University Press, New York.
34. Science Daily Newer Drugs More Effective at Curing Strep Throat Than Penicillin 2004, Retrieved 5 April 2004, from:. http://www.sciencedaily.com/releases/2004/04/040405085138.htm.
35. Shulman S.T., Tanz R., Gerber M.A. Cephalosporins are more effective than penicillin in streptococcal pharyngitis. Pediatr. Infect. Dis. J. 1994, 13:1161.
36. Stille C.J., Andrade S.E., Huang S.S., Nordin J., Raebel M.A., Go A.S., Finkelstein J.A. Increased use of second-generation macrolide antibiotics for children in nine health plans in the United States. Pediatrics 2004, 114:1206-1211.
37. Sun Q., Santoro M.A., Meng Q., Liu C., Eggleston K. Pharmaceutical policy in China. Health Aff. 2008, 27:1042-1050.
38. The World Bank Financing, Pricing, and Utilization of Pharmaceuticals in China: The Road to Retype 2010, The International Bank for Reconstruction and Development, Washington.
39. Wang Y., Li X., Lv J., Sun M., Chang F., Lin S., Hao M. To explore a breakthrough of health reform in China through changing payment (II): analysis of 'Global budget and service unit' mixed payment. Chin. Health Resour. 2011, 14:13-16.
40. Wei L. The Study on Running Mode of the Separate Management of Revenue and Expenditure of Community Health Service in Shanghai 2009, Fudan University, Shanghai.
41. Wettermark B., Persson M.E., Wilking N., Kalin M., Korkmaz S., Hjemdahl P., Gustafsson L.L. Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Serv. Res. 2010, 10:128.
42. World Health Organization How to Investigate Drug Use in Health Facilities: Selected Drug Use Indicators 1993, Retrieved 2 May 2013, from:. http://apps.who.int/medicinedocs/es/d/Js2289e/.
43. Yip W., Eggleston K. Addressing government and market failures with payment incentives: hospital reimbursement reform in Hainan, China. Soc. Sci. Med. 2004, 58:267-278.
44. Yip W., Hsiao W.C. The Chinese health system at a crossroads. Health Aff. 2008, 27:460-468.
45. Yip W.C.M., Hsiao W., Meng Q., Chen W., Sun X. Realignment of incentives for health-care providers in China. Lancet 2010, 375:1120-1130.
46. Yip W.C.M., Hsiao W.C., Chen W., Hu S., Ma J., Maynard A. Early appraisal of China's huge and complex health-care reforms. Lancet 2012, 379:833-842.
47. Yu K., Cao J., Fu H., Chen H., Zhou Y. Analysis of factors affecting physicians prescribing conduct. Chin. J. Hosp. Adm. 2002, 18:92-94.
48. Zhang Z., Tian G., Lv L., Zhang J. The analysis of Chinese drug prices issue in health care reform context. Health Econ. Res. 2012, 2:12-15.
49. Zheng M. Study on the Distribution & Control Strategy of Antimicrobial Resistance in China 2007, Huazhong University of Science and Technology, Wuhan.
50. Zhou Y., Yang H., Zhang X. Study on the influence of outpatients antibiotic expectations on doctors' prescription in Wuhan. Med. Soc. 2008, 21:3.